Table 1.
Biosimilars of infliximab, etanercept and adalimumab, licensed or in development for rheumatic diseases
| Reference product | Biosimilar | Biosimilar manufacturer | Highest development status |
|---|---|---|---|
| Infliximab | Remsima® (CT-P13) [16] | Celltrion | Licensed in EU |
| Inflectra® [17] | Hospira | Licensed in Canada, USA | |
| Inflimab® (BOW015) [20] | Epirus | Licensed in India | |
| Flixabi®/Renflexis® (SB2) [21, 22] | Samsung Bioepis/Biogen | Licensed in EU and Korea | |
| PF-06438179 [23] | Pfizer/Sandoz | Phase III | |
| ABP710 [24] | Amgen | Phase I/II | |
| Etanercept | Benepali®/Brenzys® (SB4) [19, 25] | Samsung Bioepis/ Biogen | Licensed in EU, Korea |
| Davictrel® (HD203) [26] | Hanwha/Merck | Licensed in Korea | |
| GP-2015 [27] | Sandoz | Filed in USA | |
| CHS-0214 [28] | Coherus/Baxalta | Phase III | |
| Adalimumab | Exemptia® (ZRC-3197) [29] | Zydus | Licensed in India |
| ABP501 [30] | Amgen | Filed in USA | |
| BI695501 [31] | Boehringer Ingelheim | Phase III | |
| GP-2017 [27] | Sandoz | Phase III | |
| CHS-1420 [32] | Coherus | Phase III | |
| M923 [33] | Momenta/Baxalta | Phase III | |
| SB5 [34] | Samsung Bioepis/Biogen | Phase III | |
| PF-06410293 [35] | Pfizer | Phase III | |
| Rituximab [36] | ABP 798 | Amgen | Phase III |
| AcellBia | Biocad | Licensed in Russia | |
| CT-P10 | Celltrion/Hospira | Phase III | |
| Reditux | Dr Reddy’s Laboratories | Licensed in Bolivia, Chile, India, Peru | |
| Maball | Hetero group | Licensed in India | |
| MabTas | Intas Biopharmaceuticals | Licensed in India | |
| JHL1101 | JHL Biotech | Phase I | |
| MabionCD20 | Mabion | Phase III | |
| PF-05280586 | Pfizer | Phase I/II | |
| Kikuzubam | Probiomed | Licensed in Bolivia, Chile, Mexico, Peru | |
| GP2013 | Sandoz | EU application submitted | |
| HLX01 | Shanghai Henlius Biotech | Phase III | |
| TL011 | Teva | Phase I/II | |
| Rituximab | Zenotech Laboratories | Licensed in India |
Information current as of October 2016. EU: European Union; USA, United States of America.